Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

Original publication

DOI

10.1016/j.kint.2018.06.011

Type

Journal article

Journal

Kidney Int

Publication Date

10/2018

Volume

94

Pages

663 - 673

Keywords

KDIGO, antivirals, chronic kidney disease, cryoglobulinemia, dialysis, direct-acting antivirals, glomerular diseases, guideline, hemodialysis, hepatitis C virus, infection control, kidney transplantation, liver testing, nosocomial transmission, screening, systematic review